Studieoverzicht
|
BOOG nr.: |
Status: ( Open )
|
Indication: ( Neoadjuvant )
|
Subindication: |
Menopausal status: |
| 2022-01 DIRECT-2 | Open | Neoadjuvant | HER2- HR+ | Both pre- and postmenopausal |